Journal
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY
Volume 332, Issue 6, Pages 2093-2102Publisher
SPRINGER
DOI: 10.1007/s10967-023-08903-7
Keywords
Lung cancer; Radiosensitivity; Lutetium-177; Anti-EGFR antibody; Tumor targeting
Ask authors/readers for more resources
This study investigated the radiosensitivity induced by Lu-177 and the binding affinity of cetuximab to several non-small-cell lung cancer cells (NSCLCs). Lu-177 caused apoptosis in NSCLCs through DNA double-strand damage, which was dependent on cell type. Introducing Lu-177 to the antibody enhanced its cytotoxic effect on NSCLCs. The [Lu-177]Lu-DOTA-cetuximab showed great potential for targeting diagnosis and radiotherapy in lung cancers, as demonstrated by in vivo SPECT/CT imaging and biodistribution results.
Differences in cellular radiosensitivity and the binding affinity of radiopharmaceuticals could directly affect the radiotherapeutic effects. In this study, we investigated the radionuclide (Lu-177) induced radiosensitivity of serval non-small-cell lung cancer cells (NSCLCs) as well as the binding affinity of cetuximab to those cells. The apoptosis of NSCLCs caused by Lu-177 was related to the DNA double-strand damage and was cell-type dependent. We also proved that the introduction of Lu-177 to the antibody could enhance its cytotoxic effect on NSCLCs. The [Lu-177]Lu-DOTA-cetuximab could accumulate in the HCC827 tumor xenografts with excellent stability according to in vivo SPECT/CT imaging and the biodistribution results. The [Lu-177]Lu-DOTA-cetuximab showed high potential to be used for targeting diagnosis and radiotherapy in lung cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available